Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Blood (2024) 144 (7): 714–728.

https://doi.org/10.1182/blood.2024024310

Published: 2024

Includes: Supplemental data

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone

Adam J Mead, Claire N Harrison, Brian Huntly, Bethan Psaila, Rebecca Boucher, Sonia Fox, Louise Hopkins, Joseph Rogers, Charlotte Gaskell, Amit Patel

Blood (2023) 142 (Supplement 1): 6442.

https://doi.org/10.1182/blood-2023-185798

Published: 2023

Journal Articles

Distinct and Targetable Role of Calcium and Calcium Sensing Receptor in Leukaemia

Blood (2023) 142 (Supplement 1): 5709.

https://doi.org/10.1182/blood-2023-177990

Published: 2023

Journal Articles

Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1 -Mutated Myeloid Malignancies

Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, Ivory Tang, Yanis Tazi, Amanda Gilkes, Ian Thomas, Lars Bullinger, Konstanze Döhner, Hartmut Dohner, Brian Huntly, Nigel H. Russell, Sanam Loghavi, Elli Papaemmanuil

Blood (2023) 142 (Supplement 1): 818.

https://doi.org/10.1182/blood-2023-179598

Published: 2023

Journal Articles

Hijacking of the Fibrinolytic System By B-Cell Acute Lymphoblastic Leukaemia and Its Therapeutic Targeting

Valentina Minciacchi, Christina Karantanou, Costanza Zanetti, Rahul Kumar, Theresa Krack, Nathalie Thomasberger, Pablo Llavona, Sylvia Hartmann, Veronique Maguer-Satta, Sylvain Lefort, Mateusz Putyrski, Andreas Ernst, Eshwar Meduri, Brian Huntly, Wolfram Ruf, Daniela S. Krause

Blood (2023) 142 (Supplement 1): 2781.

https://doi.org/10.1182/blood-2023-178811

Published: 2023

Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Blood (2023) 142 (Supplement 1): 2939.

https://doi.org/10.1182/blood-2023-179036

Published: 2023

Journal Articles

Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Blood (2022) 140 (Supplement 1): 5285–5287.

https://doi.org/10.1182/blood-2022-157549

Published: 2022

Journal Articles

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies

Blood (2016) 128 (1): e1–e9.

https://doi.org/10.1182/blood-2015-11-683334

Published: 2016

Includes: Supplemental data

Journal Articles

Mll-AF4 Induction during Ontogeny Reveals Early Changes in Myeloid and Lymphoid potential and Results in Hematopoietic Malignancies in Adult Mice

Neil A Barrett, MB BCh, Chrysa Kapeni, MSc, Camille Malouf, PhD, George Giotopoulos, PhD, Simon Fitch, PhD, Wendi A. Bacon, BSc, Brian Huntly, MD PhD, Katrin Ottersbach, PhD

Blood (2014) 124 (21): 892.

https://doi.org/10.1182/blood.V124.21.892.892

Published: 2014

Journal Articles

R.I.S.C.L: A Holistic Molecular Diagnostic Tool for Myeloid Malignancies

Thomas D McKerrell, MD, Ignacio Varela, PhD, Nicolo Bolli, MD PhD, Postingl Hannes, PhD, Zemin Ning, PhD, German Tischler, PhD, Anthony Bench, PhD, Bridget Manasse, PhD, Joanna Baxter, PhD, Jorge Sierra, MD PhD, Dora Foukaneli, MD PhD, Allan Warren, MD PhD, Vincenza Colona, PhD, Chris Tyler-Smith, PhD, Brian Huntly, MD PhD, Josep F. Nomdedeu, MD, Mike Scott, PhD, George Vassiliou, MD PhD

Blood (2014) 124 (21): 2342.

https://doi.org/10.1182/blood.V124.21.2342.2342

Published: 2014

Journal Articles

Modelling Resistance to Emerging Epigenetic Therapies

Blood (2014) 124 (21): 3546.

https://doi.org/10.1182/blood.V124.21.3546.3546

Published: 2014

Journal Articles

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Jyoti Nangalia, MBBChir FRCPath, Charles Massie, PhD, E Joanna Baxter, PhD, Francesca L Nice, MRes, Gunes Gundem, PhD, David Wedge, PhD, Edward Avezov, PhD, Juan Li, PhD, Karoline Kollmann, PhD, David G. Kent, PhD, Athar Aziz, PhD, Anna L Godfrey, BMBCh FRCPath, Jonathan Hinton, MSc, Inigo Martincorena, PhD, Peter Van Loo, PhD, Amy V Jones, PhD, Paola Guglielmelli, PhD MD, Patrick Tarpey, PhD, Heather P Harding, PhD, John D Fitzpatrick, BA, Calum T Goudie, BA, Christina A Ortmann, MD, Stephen J Loughran, PhD, Keiran Raine, MSc, David Jones, MSc, Adam Butler, MSc, Jon W Teague, MSc, Sarah O'Meara, Stuart McLaren, Michele Bianchi, Yvonne Silber, MSc, Danai Dimitropolou, BSc, David Bloxham, MSc FRCPath, Laura J Mudie, BSc, Mark Maddison, BSc, Ben Robinson, BSc, Clodagh Keohane, MD, Cathy MacLean, MSc, Kate Hill, BM BS, Kim H. Orchard, MBBS, PhD, FRCP, FRCPath, Sudhir Tauro, PhD, Ming-Qing Du, MB, PhD, Mel Greaves, PhD, FRS, David Bowen, MD, PhD, Brian Huntly, MBChB FRCPath PhD, Claire N Harrison, DM, FRCP, FRCPath, Nicholas C.P. Cross, PhD, FRCPath, David Ron, MD, Alessandro M Vannucchi, MD, Elli Papaemmanuil, PhD, Peter J. Campbell, PhD, Anthony R Green, FRCPath FMedSci

Blood (2013) 122 (21): LBA-2.

https://doi.org/10.1182/blood.V122.21.LBA-2.LBA-2

Published: 2013

Journal Articles

The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML)

George Giotopoulos, Wai-In Chan, David Ruau, Paolo Gallipoli, Alexis Fowler, Berthold Göttgens, Jan Van Deursen, Philip Cole, Brian Huntly

Blood (2013) 122 (21): 3732.

https://doi.org/10.1182/blood.V122.21.3732.3732

Published: 2013

Journal Articles

Modelling Cellular and Molecular Progression Of CML In The Mouse

George Giotopoulos, Louise Van Der Weyden, Hikari Osaki, Wai-In Chan, Alistair Rust, Eshwar Meduri, Steffen Koschmieder, Daniel Tenen, George Vassiliou, David Adams, Brian Huntly

Blood (2013) 122 (21): 2706.

https://doi.org/10.1182/blood.V122.21.2706.2706

Published: 2013

Journal Articles

Activity of a Heptad of Transcription Factors Is Associated with Stem Cell Programs and Clinical Outcome in Acute Myeloid Leukaemia

Blood (2012) 120 (21): 3525.

https://doi.org/10.1182/blood.V120.21.3525.3525

Published: 2012

Journal Articles

Lineage Instruction by Oncogenic Tyrosine Kinase Fusions.

Hirokazu Shigematsu, MD, PhD, Shin-ichi Mizuno, MD, Ph.D, Hiromi Iwasaki, MD, Yojiro Arinobu, MD, Ph.D, Hidetoshi Ozawa, PhD, David W. Sternberg, MD, Ph.D, Brian Huntly, MD, Ph.D, D. Gary Gilliland, MD, Ph.D, Koichi Akashi, MD, Ph.D

Blood (2005) 106 (11): 643.

https://doi.org/10.1182/blood.V106.11.643.643

Published: 2005

Journal Articles

AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.

James D. Griffin, MD, Doriano Fabbro, PhD, Gabriele Fendrich, PhD, Brian Huntly, MD, PhD, Sandra Jacob, PhD, Andrew Kung, MD, PhD, Jurgen Mestan, PhD, Ellen Weisberg, PhD, D. Gary Gilliland, MD, PhD, Paul W. Manley, PhD

Blood (2004) 104 (11): 551.

https://doi.org/10.1182/blood.V104.11.551.551

Published: 2004

NARROW

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone

Distinct and Targetable Role of Calcium and Calcium Sensing Receptor in Leukaemia

Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1 -Mutated Myeloid Malignancies

Hijacking of the Fibrinolytic System By B-Cell Acute Lymphoblastic Leukaemia and Its Therapeutic Targeting

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies

Mll-AF4 Induction during Ontogeny Reveals Early Changes in Myeloid and Lymphoid potential and Results in Hematopoietic Malignancies in Adult Mice

R.I.S.C.L: A Holistic Molecular Diagnostic Tool for Myeloid Malignancies

Modelling Resistance to Emerging Epigenetic Therapies

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML)

Modelling Cellular and Molecular Progression Of CML In The Mouse

Activity of a Heptad of Transcription Factors Is Associated with Stem Cell Programs and Clinical Outcome in Acute Myeloid Leukaemia

Lineage Instruction by Oncogenic Tyrosine Kinase Fusions.

AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only